Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Biological/Research Material for HIV Vaccine Research
Case ID:
TAB-2023
Web Published:
12/6/2022
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines.
Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques.
The list of publications shown below demonstrates the usefulness of this biological material in HIV vaccine research.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech?title=Biological%2fResearch_ Material_for_HIV_Vaccine_Research
Keywords:
239gagpol
ACXXXX
AXXXXX
DC5XXX
DCXXXX
DXXXXX
EXPRESSES
Gene
MVA/SIV239gagpol
MVNSIV239gagpoi
PJH4
recombinant
RESEARCH MATERIAL
SIV
SIV239gagpol
That
virus
Bookmark this page
Download as PDF
For Information, Contact:
Benjamin Hurley
Office of Technology Transfer Center
NIH Technology Transfer
240-669-5092
benjamin.hurley@nih.gov